Footnote i revised: Patients with a known genetic predisposition to breast cancer may have an increased risk of contralateral or ipsilateral breast cancers after breast-conservation therapy.Risk reduction strategies including prophylactic mastectomies should be discus...
基于 ASCENT 研究中 SG 展现的健康相关生活质量(HRQoL)的显著改善结果,2024 年更新的 ESMO 转移性乳腺癌在线指南 v. 1.1 版(ESMO Metastatic Breast Cancer Living Guideline V. 1.1)[3]将 SG 治疗 mTNBC 的 ESMO 临床获益量表(ESMO-MCBS)评分,由既往的 4 分调整为最高等级 5 分,这也是目前 mTNBC 二线治...
基于 ASCENT 研究中 SG 展现的健康相关生活质量(HRQoL)的显著改善结果,2024 年更新的 ESMO 转移性乳腺癌在线指南 v. 1.1 版(ESMO Metastatic Breast Cancer Living Guideline V. 1.1)[3]将 SG 治疗 mTNBC 的 ESMO 临床获益量表(ESMO-MCBS)评分,由既往的 4 分调整为最高等级 5 分,这也是目前 mTNBC 二线治...
Cancer Network, Inc., All Rights Reserved. NCCN Guidelines Version 4.2022 NCCN Guidelines Index Table of Contents Breast Cancer Discussion *William J. Gradishar, MD/Chair ‡ † Sharon H. Giordano, MD, MPH † Lori J. Pierce, MD § Robert H. Lurie Comprehensive Cancer The University of ...
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer Version 1.2024. © National Comprehensive Cancer Network, Inc 2024. All rights reserved. [Accessed January 29, 2024]. To view the most recent and complete version of the ...
01.版本说明 2019年09月06号,NCCN Guideline_Breast Cancer进行了更新,更新后版本为Version 3.2019 02.Johnson阅读的目的: 虽然本人致力于开发肿瘤免疫治疗疗法,然而,肿瘤往往存在多种免疫耐受机制,想要逆转…
While use of guideline regimens has shifted over time, there is little data to describe changes in how treatment for early-stage breast cancer has evolved over time.#In a cohort of 34,109 women treated for stage I-IIIA breast cancer between 2006鈥 2019 at Kaiser Permanente Northern ...
William J. Gradishar, MD, provides an overview of the current breast cancer treatment landscape, highlights updates to the NCCN guidelines from 2023 to 2024, and expresses optimism for addressing unmet needs at ASCO 2024. This is a modal window. The Playback API request failed for an ...
William J. Gradishar, MD, highlights the inclusion of abemaciclib in the NCCN Guidelines for select high-risk early-stage breast cancer patients, anticipates the potential for ribociclib to secure a similar guideline position, and emphasizes the importan
Now, in terms of where I would use it, if I have a patient with bona fide germline BRCA mutation, I would feel comfortable using it as a first-line or definitely as a second-line agent, particularly for triple-negative breast cancer. It’s a difficult discussion in ER-positive ...